Journal
BIOPOLYMERS
Volume 96, Issue 1, Pages 69-80Publisher
WILEY
DOI: 10.1002/bip.21480
Keywords
protecting group; cysteine; folding; solid phase
Categories
Funding
- CICYT [CTQ2009-07758]
- Generalitat de Catalunya [2009SGR 1024]
- Institute for Research in Biomedicine
- Barcelona Science Park
Ask authors/readers for more resources
Linaclotide, a small 14-mer peptide highly rich in cysteines, is currently in phase III clinical trials for the treatment of gastrointestinal disorders. The challenge in the assembly of linaclotide consists of achieving the correct and clean folding of its three disulfide bridges. For this purpose, a number of regioselective, semiregioselective, and random strategies have been studied. In addition to selecting distinct protecting groups for the thiol function, their position in the sequence, the influence of the neighboring protecting groups, as well as the order in which the disulfides fold were studied. Here we describe an optimized solid-phase synthesis of linaclotide that should allow the production of this peptide in multigram amounts. (C) 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 69-80, 2011.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available